Fractures in women treated with raloxifene or alendronate: a retrospective database analysis

BACKGROUND: Raloxifene and alendronate are anti-resorptive therapies approved for the prevention and treatment of postmenopausal osteoporosis. Raloxifene is also indicated to reduce the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk...

Descripción completa

Detalles Bibliográficos
Autores principales: Foster, Shonda A, Shi, Nianwen, Curkendall, Suellen, Stock, John, Chu, Bong-Chul, Burge, Russel, Diakun, David R, Krege, John H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626542/
https://www.ncbi.nlm.nih.gov/pubmed/23521803
http://dx.doi.org/10.1186/1472-6874-13-15

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626542/
https://www.ncbi.nlm.nih.gov/pubmed/23521803
http://dx.doi.org/10.1186/1472-6874-13-15

Ejemplares similares